The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study.

IF 7.6 2区医学 Q1 ONCOLOGY

NPJ Breast Cancer Pub Date : 2025-08-29 DOI:10.1038/s41523-025-00822-y

Kristen D Brantley, Gregory J Kirkner, Melissa E Hughes, Leticia Varella, Georgia Suggs, Olivia M Cunningham, Sanjana Ravikumar, Craig Snow, Sara M Tolaney, Sarah Sammons, Ann H Partridge, Nancy U Lin

{"title":"The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study.","authors":"Kristen D Brantley, Gregory J Kirkner, Melissa E Hughes, Leticia Varella, Georgia Suggs, Olivia M Cunningham, Sanjana Ravikumar, Craig Snow, Sara M Tolaney, Sarah Sammons, Ann H Partridge, Nancy U Lin","doi":"10.1038/s41523-025-00822-y","DOIUrl":null,"url":null,"abstract":"<p><p>The influence of young age at diagnosis on prognosis of patients with metastatic breast cancer (MBC) remains unclear. We examined overall survival (OS) within a single-institution prospective study of patients with de novo or recurrent MBC. Kaplan-Meier curves assessed OS by age (≤35 or ≤40 years as the youngest category) and inferred metastatic tumor subtype. Multivariable Cox regression models estimated hazard ratios (HRs) and 95% CIs for OS by age adjusting for clinical factors. Of 4189 women <75 years, 571 were ≤40 years at MBC diagnosis, of whom 260 were ≤35 years. Over half (52%) died during follow-up (median = 5.3 years, IQR = 2.1-9.8 years). Compared to patients 45-55 years, those ≤35 years at diagnosis experienced worse OS (HR = 1.22, 95%CI 1.00-1.48, p = 0.05). This association was driven by HER2-negative/luminal B-like and hormone receptor-positive/HER2-positive tumors. These findings highlight the need to develop more effective therapies for young patients with this metastatic subtype.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"96"},"PeriodicalIF":7.6000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397373/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41523-025-00822-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The influence of young age at diagnosis on prognosis of patients with metastatic breast cancer (MBC) remains unclear. We examined overall survival (OS) within a single-institution prospective study of patients with de novo or recurrent MBC. Kaplan-Meier curves assessed OS by age (≤35 or ≤40 years as the youngest category) and inferred metastatic tumor subtype. Multivariable Cox regression models estimated hazard ratios (HRs) and 95% CIs for OS by age adjusting for clinical factors. Of 4189 women <75 years, 571 were ≤40 years at MBC diagnosis, of whom 260 were ≤35 years. Over half (52%) died during follow-up (median = 5.3 years, IQR = 2.1-9.8 years). Compared to patients 45-55 years, those ≤35 years at diagnosis experienced worse OS (HR = 1.22, 95%CI 1.00-1.48, p = 0.05). This association was driven by HER2-negative/luminal B-like and hormone receptor-positive/HER2-positive tumors. These findings highlight the need to develop more effective therapies for young patients with this metastatic subtype.

查看原文本刊更多论文

在EMBRACE研究中，转移性乳腺癌诊断的年轻年龄与总生存率之间的关系。

诊断年龄对转移性乳腺癌（MBC）患者预后的影响尚不清楚。我们在一项针对新发或复发性MBC患者的单机构前瞻性研究中检查了总生存率。Kaplan-Meier曲线根据年龄（≤35岁或≤40岁为最年轻类别）和推断的转移性肿瘤亚型评估OS。多变量Cox回归模型通过年龄调整临床因素估计OS的风险比（hr）和95% ci。4189名女性

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Breast Cancer Medicine-Pharmacology (medical)

CiteScore

10.10

自引率

1.70%

发文量

122

审稿时长

9 weeks

期刊介绍： npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.